Today, patients with prostate cancer can be effectively treated with surgery, radiation, or androgen deprivation therapy. However, a significant fraction of patients progress to metastatic, castration-resistant prostate cancer (mCRPC), which is resistant to these treatments.
Dr. Anil Bidkar, Dr. Robert Flavell (Molecular Imaging Lab PI), and Dr. Bin Liu along with other co-authors have recently published a paper on a therapeutic strategy to address the limitations of current PSMA-directed theranostic agents for prostate cancer. Theranostics is a targeted approach to prostate cancer care that combines therapeutics and diagnostics to simultaneously or sequentially both diagnose and treat these conditions.
Currently, prostate-specific membrane antigen (PSMA)-targeted radiopharmaceuticals are the only clinically available molecules for theranostics of prostate cancer and,…
